Listed

ARS Pharmaceuticals, Inc.

SPRYNasdaqCIK 1671858HealthcareFiscal year ends Dec 31

Reports and events: 122 filings

Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.

What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.

ARS Pharmaceuticals, Inc., Reports and events
FiledFormWhat it isAccession number
2024-04-2616:02 ETDEF 14AProxy statementPeriod 2024-06-200000950170-24-049071
2024-03-2916:14 ETSC 13D/AOwnership report, active investor, amended0001104659-24-041150
2024-03-2116:09 ET10-KAnnual reportPeriod 2023-12-310000950170-24-034689
2024-03-2116:06 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000950170-24-034678
2024-03-0712:56 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-24-061842
2023-11-0916:04 ET10-QQuarterly reportPeriod 2023-09-300000950170-23-061996
2023-11-0916:02 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000950170-23-061989
2023-09-2516:30 ETSC 13D/AOwnership report, active investor, amended0001104659-23-103530
2023-09-2516:17 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-23-241345
2023-09-2006:05 ET8-K8.01 Other events0001193125-23-237996
2023-09-0116:15 ETSC 13D/AOwnership report, active investor, amended0001193125-23-227662
2023-08-3117:25 ETSC 13DOwnership report, active investor0001104659-23-097323
2023-08-1016:08 ET10-QQuarterly reportPeriod 2023-06-300000950170-23-041310
2023-08-1016:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000950170-23-041294
2023-06-2816:32 ET8-K5.07 Shareholder vote results0001193125-23-177543
2023-05-1616:31 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-23-146147
2023-05-1509:05 ET10-QQuarterly reportPeriod 2023-03-310000950170-23-021997
2023-05-1509:03 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000950170-23-021996
2023-05-0909:12 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-23-139053
2023-05-0116:30 ETDEF 14AProxy statementPeriod 2023-06-270001193125-23-130534
2023-03-2316:11 ET10-KAnnual reportPeriod 2022-12-310000950170-23-009491
2023-03-2316:09 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000950170-23-009485
2023-03-1309:26 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-23-068584
2023-02-2216:11 ET8-K1.01 Entry into a material agreement; 1.02 Termination of a material agreement0001193125-23-044823
2023-02-1406:12 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-23-036914
2023-01-1717:06 ET8-K/A9.01 Financial statements and exhibits0001193125-23-009540
2022-12-0917:02 ET8-K5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits0001193125-22-301873
2022-12-0617:07 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-22-299482
2022-11-3016:23 ETSC 13D/AOwnership report, active investor, amended0000947871-22-001216
2022-11-2116:07 ETSC 13DOwnership report, active investor0001193125-22-289924
2022-11-1817:06 ETSC 13DOwnership report, active investor0001193805-22-001578
2022-11-1814:17 ETSC 13DOwnership report, active investor0001193125-22-288763
2022-11-1814:09 ETSC 13DOwnership report, active investor0001193125-22-288750
2022-11-1813:58 ETSC 13DOwnership report, active investor0001193125-22-288740
2022-11-0816:51 ET8-K1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 3.02 Unregistered sale of equity; 5.01 Change in control; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits0001193125-22-280241
2022-11-0216:10 ET10-QQuarterly reportPeriod 2022-09-300000950170-22-021234
2022-11-0206:07 ET8-K8.01 Other events0001193125-22-275336
2022-10-2716:06 ET8-K1.01 Entry into a material agreement; 9.01 Financial statements and exhibits0001193125-22-270962
2022-10-2107:36 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001193125-22-266351
2022-09-3016:07 ET8-K1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits0001193125-22-255494
2022-09-0216:05 ET8-K5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits0001193125-22-237900
2022-08-1116:03 ET10-QQuarterly reportPeriod 2022-06-300000950170-22-016840
2022-07-2117:01 ET8-K1.01 Entry into a material agreement; 2.05 Exit or disposal costs; 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits0001193125-22-199246
2022-06-1316:32 ET8-K5.07 Shareholder vote results0001193125-22-172958
2022-05-1216:26 ET10-QQuarterly reportPeriod 2022-03-310000950170-22-009694
2022-05-1216:11 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001193125-22-148646
2022-05-0616:06 ET8-K1.02 Termination of a material agreement0001193125-22-143631
2022-04-2816:52 ETDEF 14AProxy statementPeriod 2022-06-100001193125-22-127830
2022-03-3116:11 ET10-KAnnual reportPeriod 2021-12-310000950170-22-005202
2022-03-3116:06 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001193125-22-091747

Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 10, 2026, 04:18 ET. Listed shows no prices and gives no investment advice.